Azenta Acquires UK Biocentre to Enhance Life Science Solutions and Operational Capabilities

Azenta Expands Life Science Solutions with UK Biocentre Acquisition

Azenta, Inc. solidifies its position in the life science sector with its acquisition of UK Biocentre Limited for GBP 20.5 million, a strategic move that enhances its operational capabilities in a critical market. The acquisition, executed through Azenta's subsidiary Azenta UK Ltd, not only elevates Azenta's profile in the UK but also establishes UK Biocentre as a vital operational hub. This move allows Azenta to better serve its pharmaceutical, biotechnology, academic, and public health clients throughout Europe, especially as the UK remains a significant center for life science research and innovation.

Founded in 2014, UK Biocentre specializes in sample management, sample storage, and high-throughput sample processing. The company has demonstrated considerable financial health, generating approximately GBP 15.3 million in revenue for the year ending September 30, 2025. Azenta’s acquisition capitalizes on the robust offerings of UK Biocentre, enabling the integration of advanced biorepository technologies such as the 16-million-sample BioArc™ Ultra and expanding Azenta’s end-to-end lifecycle solutions. This synergistic relationship supports not only enhanced client services but also reinforces Azenta's commitment to advancing scientific expertise and innovation in the life sciences sector.

While the integration of UK Biocentre is anticipated to have a slight dilutive effect on Azenta’s 2026 Adjusted EBITDA margin, the company projects an organic revenue boost and improved EBITDA margins by 2027 and 2028. John Marotta, Azenta's President and CEO, underscores that this acquisition solidifies the company's global reach and leadership in life sciences, capitalizing on the two organizations' combined strengths to streamline essential workflows. The strategic focus remains on delivering superior solutions for improved research outcomes in this evolving field.

In addition to enhancing its operational framework, the acquisition reaffirms UK Biocentre's commitment to scientific excellence by maintaining its original name post-acquisition. This brand recognition persists, promising continued innovation in sample management and processing within the life sciences domain. As Azenta moves forward, it aims to leverage this acquisition not only to elevate its service offerings but to establish lasting partnerships within the research community across Europe.

Azenta's commitment to integrating cutting-edge technologies and expanding its operational capabilities ensures that it stays at the forefront of life science solutions, poised for further growth and innovation in the years to come.